$0.02
+0.01(34.23%)
Mkt Cap $561.3K
$0.01
$0.17
52-Week Range
At a Glance
AI-generated8-K
NRx Pharmaceuticals issued a press release announcing a path to New Drug Application for NRX-100 (preservative-free ketamine) for Treatment-Resistant Depression in the context of suicidality, following a Type C FDA meeting, using existing clinical data and Real World Evidence from over 65,000 patients. The company anticipates NDA submission in Q2 2026 targeting full approval.$561.3K
Market Cap
$19M
Revenue
-$3.0B
Net Income
Employees2
Fundamentals
How The Business Makes Money
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Industry Biotechnology
Activity
What Changed Recently
Company Profile
CIK0001719406
ISINUS6294441182
CUSIP629444118
Phone484 254 6134
Address1201 Orange Street, Wilmington, DE, 19801, US
SEC EDGAR